These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 20654606)
1. The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels. Park H; Hasegawa G; Shima T; Fukui M; Nakamura N; Yamaguchi K; Mitsuyoshi H; Minami M; Yasui K; Itoh Y; Yoshikawa T; Kitawaki J; Ohta M; Obayashi H; Okanoue T Clin Chim Acta; 2010 Nov; 411(21-22):1735-40. PubMed ID: 20654606 [TBL] [Abstract][Full Text] [Related]
2. Fatty acid composition and estimated desaturase activities are associated with obesity and lifestyle variables in men and women. Warensjö E; Ohrvall M; Vessby B Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):128-36. PubMed ID: 16487913 [TBL] [Abstract][Full Text] [Related]
3. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014 [TBL] [Abstract][Full Text] [Related]
4. [Changes in fatty acid composition of serum cholesteryl esters in patients with chronic heart failure]. Zhao YS; Zhao SP; Tang AG Hunan Yi Ke Da Xue Xue Bao; 2003 Apr; 28(2):165-6. PubMed ID: 12934368 [TBL] [Abstract][Full Text] [Related]
6. Effect of a 2-y dietary and physical activity intervention on plasma fatty acid composition and estimated desaturase and elongase activities in children: the Physical Activity and Nutrition in Children Study. Venäläinen TM; Viitasalo AM; Schwab US; Eloranta AM; Haapala EA; Jalkanen HP; de Mello VD; Laaksonen DE; Lindi VI; Ågren JJ; Lakka TA Am J Clin Nutr; 2016 Oct; 104(4):964-972. PubMed ID: 27581473 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Abel T; Fehér J; Dinya E; Eldin MG; Kovács A Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244 [TBL] [Abstract][Full Text] [Related]
8. Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model. Oishi T; Terai S; Kuwashiro S; Fujisawa K; Matsumoto T; Nishina H; Sakaida I Biochem Biophys Res Commun; 2012 May; 422(1):22-7. PubMed ID: 22554516 [TBL] [Abstract][Full Text] [Related]
9. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391 [TBL] [Abstract][Full Text] [Related]
10. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Enjoji M; Machida K; Kohjima M; Kato M; Kotoh K; Matsunaga K; Nakashima M; Nakamuta M Lipids Health Dis; 2010 Mar; 9():29. PubMed ID: 20222991 [TBL] [Abstract][Full Text] [Related]
11. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? Ahmed MH; Byrne CD Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295 [TBL] [Abstract][Full Text] [Related]
18. Maternal low protein diet in rats programmes fatty acid desaturase activities in the offspring. Ozanne SE; Martensz ND; Petry CJ; Loizou CL; Hales CN Diabetologia; 1998 Nov; 41(11):1337-42. PubMed ID: 9833942 [TBL] [Abstract][Full Text] [Related]
19. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473 [TBL] [Abstract][Full Text] [Related]
20. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Zelber-Sagi S; Kessler A; Brazowsky E; Webb M; Lurie Y; Santo M; Leshno M; Blendis L; Halpern Z; Oren R Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]